Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Skirmishes Heat Up between Pro- and Anti-Online Drug Sale Camps
March 2, 2009
- Project Begun in Order to Verify Usefulness of MD Studies
March 2, 2009
- Group of LDP Lawmakers to Draft Bill to Restrict Online Sale of OTC Drugs
March 2, 2009
- Shionogi's Velneperit Meets Primary Endpoint in 2 PIIb Trials
March 2, 2009
- Gov't to Issue Action Program and GL for New-Type Influenza
March 2, 2009
- R&D NEWS IN BRIEF
March 2, 2009
- Tamiflu-Resistant Influenza Virus Spreading in Japan
March 2, 2009
- National Cancer Center Posts Generics It Uses on Its Website
March 2, 2009
- No Causal Relation between Tamiflu and Abnormal Behavior: WG on Basic Studies
March 2, 2009
- HPV Vaccination Should Be Provided at Government Expense
March 2, 2009
- Sanofi-aventis Seeks Top-Five Place in Japan
March 2, 2009
- Training Courses on CKD Planned for Healthcare Providers
March 2, 2009
- Eisai Licenses Zebinix for Epilepsy from Bial-Portela
March 2, 2009
- TOPICS 2 articles
March 2, 2009
- Chugai Licenses Nitazoxanide from Romark Lab.
March 2, 2009
- Acquisition of Local Company an Option for Marketing Lurasidone in US: DSP
March 2, 2009
- GSK to Tie Up with Nippon Kayaku to Market Lapatinib in Japan
March 2, 2009
- Mr Shoda Feels the Pinch of the Global Financial Crisis
March 2, 2009
- SELF-MEDICATION NEWS IN BRIEF
February 23, 2009
- Five Factors Responsible for Drug Lag: Mr Sekiguchi
February 23, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…